Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in Stage I lung adenocarcinoma

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2362-2368

  Tomizawa, Yoshio ^a,c   Kohno, Takashi ^a   Kondo, Haruhiko ^b   Otsuka, Ayaka ^a   Nishioka, Michiho ^a   Niki, Toshiro ^a   Yamada, Tesshi ^a   Maeshima, Arafumi ^a   Yoshimura, Kimio ^a   Saito, Ryusei ^c   Minna, John D ^d   Yokota, Jun ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c GUNMA UNIVERSITY   (Japan)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER; PROTEIN P53; MICROSATELLITE DNA; PRIMER DNA; RASSF1 PROTEIN, HUMAN; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ALLELIC IMBALANCE; ARTICLE; CANCER STAGING; CHROMOSOME 3P; CHROMOSOME DELETION; CHROMOSOME INACTIVATION; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; METHYLATION; ONCOGENE K RAS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; ADENOCARCINOMA; CASE CONTROL STUDY; CHEMISTRY; CHROMOSOME 3; COMPARATIVE STUDY; CPG ISLAND; DNA METHYLATION; GENE SILENCING; GENETICS; HETEROZYGOSITY LOSS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MUTATION; ONCOGENE RAS; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; AGED; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 3; COMPARATIVE STUDY; CPG ISLANDS; DNA METHYLATION; DNA PRIMERS; FEMALE; GENE SILENCING; GENES, RAS; GENES, TUMOR SUPPRESSOR; HUMAN; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MICROSATELLITE REPEATS; MIDDLE AGE; MUTATION; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PROTEIN P53; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; HUMANS; MIDDLE AGED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0035992419     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. How many tumor suppressor genes are involved in human lung carcinogenesis?
2. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer
3. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer
4. Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung
5. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints
6. Three distinct regions involved in 3p deletion in human lung cancer
7. Definition of a tumor suppressor locus within human chromosome 3p21-p22
8. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: Identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium
9. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3
10. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression
11. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis
12. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumors
13. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas
14. Lung cancer
15. Cigarette smoking and changes in the histopathology of lung cancer
16. Survival in early-stage non-small cell lung cancer
17. Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung
18. International Union Against Cancer (UICC): Lung (ICD-0 C-34)
19. Baylin a novel PCR assay for methylation status of CpG islands
20. Aberrant promoter methylation of multiple genes in non-small cell lung cancers
21. Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis
22. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer
23. Progress in understanding the molecular pathogenesis of human lung cancer
24. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: A meta-analysis
25. Small adenocarcinoma of the lung. Histologic characteristics and prognosis
26. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers
27. Cancer epigenetics comes of age
28. Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns
29. Functional properties of a new voltage-dependent calcium channel α(2)δ auxiliary subunit gene (CACNA2D2)
30. Molecular cloning of a candidate tumor suppressor gene, DLCI, from chromosome 3p21.3
31. Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B
32. Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas
33. 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer
34. p53 and ATM: Cell cycle, cell death, and cancer